Bioadaptives, Inc. (BDPT) Cash & Equivalents (2013 - 2026)

Bioadaptives has reported Cash & Equivalents for 13 years, with the latest figure at $73606.0 in Q1 2026.

• Quarterly Cash & Equivalents rose 86.04% year-over-year to $73606.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73606.0 (up 86.04% YoY) and the FY2025 annual result came in at $158445.0, up 15.26% from the prior year.
• Cash & Equivalents retreated to $73606.0 in Q1 2026 per BDPT's latest filing, from $158445.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $210582.0 in Q2 2025 and troughed at $235.0 in Q2 2024.
• A 5-year average of $67456.0 and a median of $44450.0 in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 99.41% in 2024, then surged 89509.36% in 2025.
• Over 5 years, Cash & Equivalents stood at $25405.0 in 2022, then surged by 139.23% to $60776.0 in 2023, then jumped by 126.19% to $137470.0 in 2024, then advanced by 15.26% to $158445.0 in 2025, then plunged by 53.54% to $73606.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $73606.0, $158445.0, and $59273.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.